Category: tools-profils-members

PhD, Scientific advisor   John C. Bell, PhD, is an internationally renowned expert in using oncolytic viruses (OVs) to treat cancer. He formed, and continues to lead, the Canadian Oncolytic Virus Consortium, a trans-Canadian, multidisciplinary group developing virus-based cancer therapeutics. He is the Scientific Director of BioCanRx, a Network of Centers of Excellence developing and… Continue reading John Bell

MD, Scientific advisor    Pedro Romero, MD, is Professor at the Faculty of Biology and Medicine, University of Lausanne, where he has worked since 2003, focusing on tumor immunology and cancer immunotherapy, particularly on the biology and dynamics of cytolytic CD8 T lymphocyte (CTL) responses. He is also Editor-in-Chief of the Journal for ImmunoTherapy of Cancer.… Continue reading Pedro Romero

Director  Laurence Espinasse has been the Legal Director of Institut Mérieux since 2021. She practiced as a lawyer for more than 15 years in the law firm MDL, of which she was a partner. Laurence Espinasse also practiced at Ernst & Young where she was involved in complex legal transactions, such as M&A and Restructuring,… Continue reading Laurence Espinasse

Independent Director  Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads the LYriCAN project (integrated cancer research)… Continue reading Prof. Jean-Yves Blay

Independent Director and non-executive Chairman Dr. Riva has nearly 30 years’ experience in the Life Sciences industry and is currently CEO of Intima Bioscience which specializes in cell therapies for solid cancers. Prior to this role, he served as CEO of Ichnos Sciences and Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell… Continue reading Dr. Alessandro Riva

MD, Independent Director Laurence Zitvogel, MD, is a professor of immunology and biology at Paris University (Université de Paris Saclay). An oncologist and researcher at Institut Gustave Roussy since 1995, she is internationally renowned for her work in anti-tumor immunology; she has led Phase I and Phase II clinical studies in cancer immunotherapy and deciphered… Continue reading Dr. Laurence ZITVOGEL

Director, represented by Sandrine FLORY TSGH SAS has been Transgene’s reference shareholder since 1994. This financial holding company is a member of Institut Mérieux Group and is in fine owned by the Mérieux family and by the Christophe and Rodolphe Mérieux Foundation. Philippe Archinard is CEO of TSGH. Sandrine Flory has been TSGH’s permanent representative… Continue reading Sandrine Flory TSGH

Independent Director Maya Said has been an independent Director of Transgene since 2017. She brings more than 15 years of international experience in the healthcare industry. Previously, she was Vice-President, Senior Global Head of Oncology Policy and Market Access at Novartis, and Vice President, Head of Strategy, Science Policy & External Innovation, Global R&D at… Continue reading Maya SAID

Honorary Chairman Alain Mérieux is Chairman of Institut Mérieux, a family holding company dedicated to medicine and public health worldwide. In 1963, Alain Mérieux founded bioMérieux, an in vitro diagnostics company. From 1968 to 1994, he was Chairman of Institut Mérieux, which specialized in human and veterinary vaccines, before divesting the vaccine business. In 1994,… Continue reading Alain MÉRIEUX

Independent Director, Chairwoman of the Audit Committee Marie Landel founded Marie Landel & associates, now Axelia Partners, a consultancy based in Cambridge (Massachusetts) specialized in advising European companies on the creation and development of US subsidiaries. She has significant experience supporting French and European biotechnology companies in the United States. With more than 30 years… Continue reading Marie LANDEL